Cargando...
Targeting SDF-1/CXCL12 with a ligand that prevents activation of CXCR4 through structure based drug design
[Image: see text] CXCL12 is an attractive target for clinical therapy because of its involvement in autoimmune diseases, cancer growth, metastasis, and neovascularization. Tyrosine sulfation at three positions in the CXCR4 N-terminus is crucial for specific, high-affinity CXCL12 binding. An NMR stru...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2010
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2941798/ https://ncbi.nlm.nih.gov/pubmed/20459090 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/ja1002263 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|